# Every Other Week: Stretching the Interval

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-19 | Updated: 2026-11-01

Canonical page: https://glpwatchdog.org/research/every-other-week-dosing

> Patients moved to every-other-week dosing after a plateau held their weight and body composition over 36 weeks. It is a case series with no control group, and it is the third of three different ways to use less drug.

## Key points

- Weight 87.9 kg → 74.1 at plateau → 72.4 on every-other-week dosing, over ~36 weeks.
- Case series: no control, no randomization, and clinicians choose who to step down.
- Three distinct strategies: microdose, lower labeled dose, longer interval. Only the middle one is randomized.
- Long half-lives make the idea reasonable: dosing every two weeks does not mean two weeks without drug.

There are three different ways to use less drug, and they keep getting confused. You can take a dose below the labeled range, which is [microdosing](https://glpwatchdog.org/research/glp1-microdosing-what-evidence-exists) and has no trials. You can step down to a lower labeled dose, which has been [tested and randomized](https://glpwatchdog.org/research/tirzepatide-maintenance-dose-trial). Or you can keep the same dose and stretch the interval. The pharmacology of why that might work at all, and what the modeling behind it consists of, is in [stretching doses to save money](https://glpwatchdog.org/research/stretching-doses-to-save-money). A 2026 report looked at the third approach, and it is a **case series**.

## What was observed

Patients who had plateaued on weekly semaglutide or tirzepatide were moved to reduced-frequency dosing at their existing dose, usually every other week, and followed for an average of 36.3 weeks.[1]

*Body weight across the three time points in the case series.*

| Point | Weight |
| --- | --- |
| Before treatment | 87.9 ± 2.4 kg |
| Plateau, on weekly dosing | 74.1 ± 2.4 kg |
| Maintenance, on reduced frequency | 72.4 ± 2.2 kg |

Weight not only held but fell slightly further. Total body fat and truncal fat declined, skeletal muscle mass stabilized, and the metabolic improvements gained during weekly dosing were maintained.[1]

## Why this cannot carry the weight people will put on it

A case series is a description of what happened to a group of patients someone chose to write up. There is no control group, no randomization, and no comparator arm continuing weekly dosing alongside them.

- **Selection.** Clinicians move patients who are doing well onto reduced frequency. Patients doing well continue doing well. That alone could produce this entire result.
- **No counterfactual.** Nobody knows what these same patients would have weighed had they stayed weekly. It could have been less.
- **Everyone had already plateaued.** This says nothing about stretching the interval during active weight loss, which is when most people would want to.
- **Small and unblinded**, with outcomes measured in a clinic that chose the intervention.

> “Reduced-frequency dosing maintains weight” is exactly the sentence a cheaper subscription tier wants. A case series cannot supply it.

## Why it is still worth knowing

The underlying idea is pharmacologically reasonable and under-tested. These drugs have long half-lives (semaglutide’s is about a week), so a fortnightly interval is not the same as a fortnight without drug. Enough remains between doses that the concept is not absurd, and the randomized dose-reduction evidence points the same general way: less drug held much of the loss.

It also matters practically. Cost is a leading reason people stop. In one US health system, cost or insurance problems were the most common recorded reason, behind almost half of the first-year discontinuations reviewed.[2] Stopping entirely produces a much worse outcome than any reduced-intensity strategy tested so far. A structured de-escalation supervised by a prescriber is a different thing from quietly stretching doses to make a vial last, and this report is an argument for studying the first properly rather than for improvising the second.

> **The version of this that goes wrong is unsupervised.** Stretching an interval to save money, without anyone measuring what happens, is not what this describes. These patients were monitored, with body composition and metabolic markers tracked at each stage. If the appeal is affordability, that is a conversation to have out loud with a prescriber, because it is a clinical decision with a cost motive rather than the reverse.

## Frequently asked questions

### Can you inject a GLP-1 every other week?

Some clinicians do it for maintenance after a plateau, and a 2026 case series reported that weight, body composition and metabolic improvements held over an average of 36 weeks. It is a case series with no control group, so it describes what happened rather than establishing that the approach works.

### Is this the same as microdosing?

No, and the three get confused constantly. Microdosing means a dose below the labeled range. Dose reduction means a lower labeled dose, which has randomized evidence. This is a third thing, the same dose at a longer interval, and nobody has randomized it.

### Why might a longer interval work at all?

These drugs have long half-lives (semaglutide's is roughly a week), so a fortnightly interval is not a fortnight without drug. Meaningful concentration remains between doses, which makes the idea pharmacologically reasonable even though it is untested.

### Would it work while still losing weight?

Unknown. Everyone in the series had already plateaued before switching, so it says nothing about stretching the interval during active weight loss, which is when most people would want to.

### Is it a reasonable way to save money?

It is a reasonable thing to raise with a prescriber, given that cost is a leading reason people stop entirely and stopping produces a clearly worse outcome. What this report describes is supervised de-escalation with body composition and metabolic markers tracked, not stretching doses quietly to make a vial last.

## References

1. Wong M, Wu A, Garhe PK, et al. Reduced-Frequency GLP1 Therapy Maintains Weight, Body Composition, and Metabolic Syndrome Improvements: A Case Series. Obesity. 2026. PMID: 41732031. https://pubmed.ncbi.nlm.nih.gov/41732031/
2. Gasoyan H, Butsch WS, Casacchia NJ, et al. Reasons for Discontinuation of Obesity Pharmacotherapy With Semaglutide or Tirzepatide in Clinical Practice. Obesity. 2025. PMID: 41039650. https://pubmed.ncbi.nlm.nih.gov/41039650/

---

Cite as: GLP Watchdog, Nora Bissett, "Every Other Week: Stretching the Interval", published 2026-08-19, updated 2026-11-01. https://glpwatchdog.org/research/every-other-week-dosing

Canonical HTML page: https://glpwatchdog.org/research/every-other-week-dosing

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
